Hepion Pharmaceuticals (HEPA) Scheduled to Post Earnings on Thursday

Hepion Pharmaceuticals (NASDAQ:HEPA) will release its earnings data on Thursday, April 4th.

Hepion Pharmaceuticals Trading Down 3.0 %

Shares of NASDAQ HEPA opened at $2.29 on Wednesday. The company has a 50-day moving average price of $2.20 and a 200-day moving average price of $3.18. Hepion Pharmaceuticals has a 1 year low of $1.49 and a 1 year high of $20.66.

Institutional Investors Weigh In On Hepion Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the company. Virtu Financial LLC bought a new stake in Hepion Pharmaceuticals in the 4th quarter worth about $41,000. Renaissance Technologies LLC grew its position in shares of Hepion Pharmaceuticals by 15.8% during the 1st quarter. Renaissance Technologies LLC now owns 284,300 shares of the company’s stock valued at $221,000 after acquiring an additional 38,700 shares during the period. BlackRock Inc. grew its position in shares of Hepion Pharmaceuticals by 0.3% during the 1st quarter. BlackRock Inc. now owns 1,602,772 shares of the company’s stock valued at $1,245,000 after acquiring an additional 5,206 shares during the period. Envestnet Asset Management Inc. grew its position in shares of Hepion Pharmaceuticals by 131.9% during the 4th quarter. Envestnet Asset Management Inc. now owns 202,978 shares of the company’s stock valued at $61,000 after acquiring an additional 115,437 shares during the period. Finally, State Street Corp grew its position in shares of Hepion Pharmaceuticals by 8.1% during the 1st quarter. State Street Corp now owns 348,910 shares of the company’s stock valued at $450,000 after acquiring an additional 26,194 shares during the period. 17.24% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, Brookline Capital Management downgraded shares of Hepion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, December 7th.

About Hepion Pharmaceuticals

Hepion Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms.